nature portfolio

Corresponding author(s):	Shihui Niu	
Last updated by author(s):	Mar 22, 2023	

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

_				•
U 1		-	ıst	100
_	_		_	11 \

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	\square The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\boxtimes	A description of all covariates tested
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

No software was used in data collection

Data analysis

BS-seq, RNA-seq, and sRNA-SEQ analysis:Trimmomatic version 0.32, Bismark version 0.20.0, Bowtie2 version2.3.5.l, BatMeth2, FastQC versionv0.11.7, HISAT version 2.2.1, StringTie version 2.1.5, Bowtie version 1.3.1 Data visualization: Integrative Genomics Viewer version 2.1.24

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

All data supporting the findings of this study are available within the manuscript and its supplementary files. All high-throughput sequencing data generated in this study have been deposited in SRA database. The accession numbers for the BS-seq data are PRJNA858924 (https://www.ncbi.nlm.nih.gov/bioproject/?

	accession number	99 (https://www.ncbi.nlm.nih.gov/search/all/?term=PRJNA785099). The accession number for the RNA-seq data is s for the smRNA-seq data are PRJNA858924 and PRJNA785122 (https://www.ncbi.nlm.nih.gov/bioproject/?			
Human rese	arch parti	cipants			
Policy information	about <u>studies i</u>	nvolving human research participants and Sex and Gender in Research.			
Reporting on sex and gender		NA			
Population characteristics		NA			
Recruitment		NA			
Ethics oversight		NA			
Field-spe		poval of the study protocol must also be provided in the manuscript. Porting			
Please select the o	ne below that i	s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
X Life sciences	B	ehavioural & social sciences			
For a reference copy of	the document with	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>			
Life scier	nces sti	udy design			
All studies must dis	sclose on these	points even when the disclosure is negative.			
Sample size	Sample size in all the experiments was sufficient for statistical significance and reproducib (2)ty. For BS-seq, two biological replicates were collected for each age sample. For RNA-seq and sRNA-seq, three biological replicates were collected for each age sample				
Data exclusions	No data were e	xcluded from the analysis			
Replication	BS-seq was per	formed with two biological replicates. RNA-seq and sRNA-seq were performed with three biological replicates.			
Randomization	All the samples	All the samples were collected from naturally growing trees, no horticulture measures, such as rootstock grafting, were used.			
Blinding	No blinding was used. When processing the sequencing data, the same parameters were applied. There was no possible manual intervention				
We require informati	ion from authors	Decific materials, systems and methods about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.			
·					
Materials & experimental systems n/a Involved in the study Methods n/a Involved in the study					
Eukaryotic					
Animals and other organisms Clinical data					
	esearch of conce	n			